Michael Curtis, PhD2018-12-06T15:10:26+00:00

Michael Curtis, PhD

President and CEO

Michael Curtis is the President and Chief Executive Officer of Cadent with over 25 years of experience in bringing novel treatments to patients. Prior to joining Cadent, he was Senior Vice President of Product Development and Regulatory Affairs at Catabasis Pharmaceuticals with responsibility for all as aspects of moving the company’s products from research into clinical development. He was previously Vice President of Pharmaceutical Development at Infinity Pharmaceuticals, with responsibility for manufacturing, formulation, analytical and drug metabolism / pharmacokinetics. Prior to Infinity he was with Transkayotic Therapies (currently Shire) and Genzyme leading activities that resulted in the registration of lysosomal disease therapies Elaprase® (idursulfase) and Myozyme® (alglucosidasealfa).  He led Analytical Development at Syntonix Pharmaceuticals (currently Biogen), where he was involved with advancing the Transceptor™ technology culminating in the development of Eloctate™ (rFVIIFc) and Alprolix™ (rFIXFc). Dr. Curtis began his career at Bristol-Myers Squibb, with positions of increasing responsibility working in small molecule and biologics development, most significantly on the manufacturing processes for Capoten® (captopril), Taxol® (paclitaxel) and the early development of Orencia® (abatacept).

Michael earned his Ph.D. in cell and molecular biology from Upstate Medical University.

Our Team

Michael Curtis, PhD

President and CEO

Michael Curtis is the President and Chief Executive Officer of Cadent with over 25 years of experience in bringing novel treatments to patients. Prior to joining Cadent, he was Senior Vice President of Product Development and Regulatory Affairs at Catabasis Pharmaceuticals with responsibility for all as aspects of moving the company’s products from research into clinical development. He was previously Vice President of Pharmaceutical Development at Infinity Pharmaceuticals, with responsibility for manufacturing, formulation, analytical and drug metabolism / pharmacokinetics. Prior to Infinity he was with Transkayotic Therapies (currently Shire) and Genzyme leading activities that resulted in the registration of lysosomal disease therapies Elaprase® (idursulfase) and Myozyme® (alglucosidasealfa).  He led Analytical Development at Syntonix Pharmaceuticals (currently Biogen), where he was involved with advancing the Transceptor™ technology culminating in the development of Eloctate™ (rFVIIFc) and Alprolix™ (rFIXFc). Dr. Curtis began his career at Bristol-Myers Squibb, with positions of increasing responsibility working in small molecule and biologics development, most significantly on the manufacturing processes for Capoten® (captopril), Taxol® (paclitaxel) and the early development of Orencia® (abatacept).

Michael earned his Ph.D. in cell and molecular biology from Upstate Medical University.

Our Team

Michael Curtis, PhD

President and CEO

Michael Curtis is the President and Chief Executive Officer of Cadent with over 25 years of experience in bringing novel treatments to patients. Prior to joining Cadent, he was Senior Vice President of Product Development and Regulatory Affairs at Catabasis Pharmaceuticals with responsibility for all as aspects of moving the company’s products from research into clinical development. He was previously Vice President of Pharmaceutical Development at Infinity Pharmaceuticals, with responsibility for manufacturing, formulation, analytical and drug metabolism / pharmacokinetics. Prior to Infinity he was with Transkayotic Therapies (currently Shire) and Genzyme leading activities that resulted in the registration of lysosomal disease therapies Elaprase® (idursulfase) and Myozyme® (alglucosidasealfa).  He led Analytical Development at Syntonix Pharmaceuticals (currently Biogen), where he was involved with advancing the Transceptor™ technology culminating in the development of Eloctate™ (rFVIIFc) and Alprolix™ (rFIXFc). Dr. Curtis began his career at Bristol-Myers Squibb, with positions of increasing responsibility working in small molecule and biologics development, most significantly on the manufacturing processes for Capoten® (captopril), Taxol® (paclitaxel) and the early development of Orencia® (abatacept).

Michael earned his Ph.D. in cell and molecular biology from Upstate Medical University.

Our Team